Oncolytics Biotech Inc.

ONCY • Biotechnology

$0.84

▼ -0.01 (-1.55%)

Precio actual

ResultadosÚltimo reporte: 30 jun 2026

PERFIL DÉBILDébilConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Perfil histórico débil. La evidencia actual no sostiene una relación riesgo/retorno favorable.

Capitalización

$100.96M

Crecimiento

—

Flujo de caja

0/5

Tendencia

Negative

Evidencia

Rentabilidad débil

Datos financieros hasta: 30 jun 2026, 12:00 a.m. UTCÚltima actualización de earnings: 30 jun 2026, 12:00 a.m. UTCÚltima actualización del perfil: 16 ago 2026, 12:10 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$0.84

Change-1.55%

Shares Out119.74M

Market Cap$100.96M

Enterprise Value$97.30M

52W Range0.73 - 1.51

Beta1.14

P/E-2.60

P/B-16.37

P/FCF-3.29

EV/EBITDA-2.44

EV/FCF-3.17

Price$0.84

Change-1.55%

Shares Out119.74M

Market Cap$100.96M

Enterprise Value$97.30M

52W Range0.73 - 1.51

Beta1.14

P/E-2.60

P/B-16.37

P/FCF-3.29

EV/EBITDA-2.44

EV/FCF-3.17

Earnings Yield-38.43%

FCF Yield-30.39%

Dividend Yield0.00%

Gross Margin0.00%

Oper. Margin0.00%

Profit Margin0.00%

Debt/Eq-0.15

Current Ratio1.12

Quick Ratio1.12

Volume1.12M

Avg Volume1.33M

EPS Surprise-0.03

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

49/100

Potencial de crecimiento

Ingresos y expansión

50/100

Atractivo del precio

Barata o cara hoy

50/100

Por qué este puntaje▼

Rentabilidad débil

Analyst view

Analyst sentiment and price target

ONCY

Analyst sentiment

Based on 10 analyst votes · 2026-09-05

90/100

Bullish

Hold

Bearish

Resumen de la compañía

IPO: 10/5/2001

Industria: Biotechnology

P/B i: -16.37

Deuda / Patrimonio i: -0.15

Margen operativo: 0.00%

Margen neto: 0.00%

ROE i: -

ROIC: -

Salud financiera

Puntaje10 / 20

Deuda / Patrimonio: -0.15

Ratio corriente: 1.12

Ratio rápido: 1.12

Estado: Moderate

Transacciones internas

Actividad reciente de ejecutivos e insiders

Glover Stephen C.

Transacción: 06/01/2026

OTRO

Cambio

Precio

Not reported

Presentación

06/03/2026

Tipo

OTRO

McAdory John Bearden

Transacción: 06/01/2026

OTRO

Cambio

+500,000

Precio

$0.97

Presentación

06/03/2026

Tipo

OTRO

Kelly Jared

Transacción: 03/12/2026

COMPRA

Cambio

+5,050

Precio

$0.96

Presentación

03/13/2026

Tipo

COMPRA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
Glover Stephen C.	OTRO	0	Not reported	06/01/2026	06/03/2026
McAdory John Bearden	OTRO	+500,000	$0.97	06/01/2026	06/03/2026
Kelly Jared	COMPRA	+5,050	$0.96	03/12/2026	03/13/2026
Parsons James T.	COMPRA	+10,000	$1.03	03/11/2026	03/13/2026
Andrews Patricia S	COMPRA	+35,400	$0.86	02/12/2026	02/13/2026
Seizinger Bernd R.	COMPRA	+40,000	$0.85	02/12/2026	02/13/2026
Hagerman Allison	COMPRA	+10,000	$0.83	02/12/2026	02/13/2026
Brown Deborah Margaret	COMPRA	+25,000	$0.85	02/12/2026	02/13/2026
Heineman Thomas Charles	COMPRA	+12,132	$0.83	02/12/2026	02/13/2026
Pisano Wayne	COMPRA	+30,000	$0.84	02/12/2026	02/13/2026
Look Kirk	COMPRA	+12,000	$0.84	02/12/2026	02/13/2026
Kelly Jared	COMPRA	+29,500	$0.84	02/12/2026	02/13/2026
Aromando Andrew	COMPRA	+29,600	$0.86	02/11/2026	02/13/2026
Seizinger Bernd R.	COMPRA	+60,000	$0.83	02/11/2026	02/13/2026
Kelly Jared	COMPRA	+5,600	$0.84	02/11/2026	02/13/2026
Seizinger Bernd R.	COMPRA	+100,000	$1.04	01/16/2026	01/20/2026
RIGBY JONATHAN	OTRO	+45,000	$1.84	01/01/2026	01/02/2026
RIGBY JONATHAN	OTRO	0	Not reported	01/01/2026	01/02/2026
Aromando Andrew	OTRO	+250,000	$0.99	01/01/2026	01/02/2026
Aromando Andrew	OTRO	0	Not reported	01/01/2026	01/02/2026

Sobre la compañía

Oncolytics Biotech Inc.

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.

Fuente - Link

Competidores

ATOS CLNN COYA IMMX MGNX SRZN TIL TVGN WHWK ZNTL

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Oncolytics Biotech® Aligns with FDA on Registrational Path for Second-Line RAS-Mutant MSS Colorectal Cancer

FDA written feedback provides alignment on a potential pivotal Part B expansion of the ongoing REO 033 study Proposed pathway offers potential accelerated approval based on objective response rate and progression-free survival supporting full approval Pivotal expansion to follow initial clinical data from the ongoing randomized Part A SAN DIEGO, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced that it has received written feedback from the U.S. Food and Drug Administration (“FDA”) regarding the design of a potential pivotal Part B expansion of REO 033, the Company's ongoing randomized study evaluating pelareorep in second-line RAS-mutant, microsatellite stable (“MSS”) metastatic colorectal cancer (“REO 033”). The Company submitted a Type D meeting request to the FDA regarding the potential expansion of REO 033 into a pivotal study.

GlobeNewsWire

Oncolytics Biotech® Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal Cancer

Designation supports development in an estimated $1 billion market where there are no FDA-approved therapies for patients whose disease progresses following first-line standard of care therapy Third Fast Track designation in gastrointestinal cancers strengthens Oncolytics' regulatory momentum and continues to advance the Company's path toward registration SAN DIEGO, July 20, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation to pelareorep in combination with a checkpoint inhibitor for the treatment of patients with inoperable, locally recurrent or metastatic squamous cell carcinoma of the anal canal (“SCAC”) who have progressed on or were intolerant to one or more prior lines of systemic therapy. Fast Track designation is intended to facilitate the development and expedite the review of therapies that treat serious diseases and address significant unmet medical needs.

GlobeNewsWire

Oncolytics Biotech® Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial

Half of planned clinical sites will be activated this month; more than 20 patients have been pre-identified across participating centers Company to hold Type D meeting with FDA to discuss a potential registrational pathway through the addition of Part B to the existing REO 033 trial design Part B will be a randomized study designed to support potential accelerated and full approval SAN DIEGO, July 13, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, an investigational, systemically active immunotherapy that promotes potentially protective immune responses, including the upregulation of key inflammatory cytokines resulting in the formation of tertiary lymphoid structures and the expansion of tumor-infiltrating lymphocytes, today provided a clinical and regulatory update on REO 033, the Company's randomized controlled study evaluating pelareorep in combination with folinic acid, fluorouracil and irinotecan (“FOLFIRI”) and bevacizumab for the second-line treatment of patients with Rat Sarcoma (“RAS”)-mutant, microsatellite stable (“MSS”) metastatic colorectal cancer. REO 033 builds upon the previously reported REO 022 study, which more than doubled historical standard-of-care benchmarks across progression-free survival, overall survival, duration of response, and objective response rate.1 -4 Based on these data, pelareorep has received Fast Track designation from the U.S. Food and Drug Administration (“FDA”) for this indication.

GlobeNewsWire

Oncolytics Biotech® Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044

Intellectual property update confirms pelareorep's unique manufacturing process and scalability Previously filed method-of-use patent application expected to provide protection into 2046 Additional patent filings planned in 2026 to further expand the pelareorep intellectual property estate SAN DIEGO, June 16, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, an investigational, systemically active immunotherapy that promotes potentially protective immune responses, including the upregulation of key inflammatory cytokines resulting in the formation of tertiary lymphoid structures and the expansion of tumor-infiltrating lymphocytes, today announced that the United States Patent and Trademark Office (“USPTO”) has issued a new patent broadly protecting the Company's proprietary manufacturing process for pelareorep. The newly issued patent covers key aspects of the methods used to manufacture pelareorep and is expected to provide intellectual property protection into 2044.

GlobeNewsWire

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-14	-0.05	-0.08	-0.03
2026-03-30	-0.06	-0.08	-0.02
2025-11-12	-0.12	-0.1	0.02
2025-08-08	-0.11	-0.05	0.06
2025-05-14	-0.09	-0.06	0.03
2025-03-07	-0.08	-0.07	0.01
2024-11-12	-0.08	-0.09	-0.01
2024-08-01	-0.08	-0.07	0.01
2024-05-09	-0.09	-0.07	0.02
2024-03-07	-0.11	-0.04	0.07
2023-11-03	-0.07	-0.1	-0.03
2023-08-14	-0.09	-0.09	0